• Allergy , 
• ILC3 Deficiency and Generalized ILC Abnormalities in DOCK8 Deficient Patients

  Abstract Background Dedicator of cytokinesis 8 (DOCK8) deficiency is the main cause of the autosomal recessive hyper IgE syndrome (HIES). We previously reported the selective loss of group 3 innate lymphoid cell (ILC) number and function in a Dock8‐deficient mouse model. In this study, we sought to test whether DOCK8 is required for the function and maintenance of ILC subsets in humans. Methods Peripheral blood ILC1‐3 subsets of 16 DOCK

  Allergy

  Wed Oct 09, 2019 07:09
• Allergy
• Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients

  Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and h...

  Allergy

  Thu Oct 10, 2019 17:00
• Correction to: ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

  Following publication of the original article [1], the authors reported that one of the authors’ names was spelled incorrectly. In this Correction the incorrect and correct author name are shown. In the author...

  Allergy

  Wed Oct 09, 2019 17:00
• Annals of Allergy, Asthma & Immunology
• Drug Hypersensitivity testing: Baboon Syndrome precipitated by amoxicillin challenge

  Although beta-lactam ‘allergy’ may be self-reported in up to 10% of individuals, only a minority of these individuals (3-5 %) will have genuine type 1 IgE-mediated hypersensitivity.1

  Annals of Allergy, Asthma & Immunology

  Wed Oct 09, 2019 17:00
• Rapid Desensitization of Hydroxychloroquine

  Hydroxychloroquine (HCQ, Plaquenil®) is an antimalarial agent with immunosuppressive and cytotoxic properties that is considered safe and effective in pregnant patients with a history of mild lupus nephritis (LN).1-2 Hypersensitivity to hydroxychloroquine usually manifests as maculopapular exanthems within two to 33 days and rarely as eosinophilia or other systemic symptoms.3 Several prolonged desensitization protocols, ranging from four to 36 da

  Annals of Allergy, Asthma & Immunology

  Wed Oct 09, 2019 17:00
• Clinical & Experimental Allergy
• Efficacy of air cleaners in asthmatics allergic to cat in ALYATEC® Environmental Exposure Chamber

  Abstract Background Air cleaners have been promoted for respiratory allergic disease prevention, but there is no clear clinical proof of their efficacy in allergic asthma. Objective To examine the efficacy of a new air cleaner on early and late asthmatic responses in cat‐allergic patients. Methods This randomized, cross‐over, double‐blind placebo‐controlled study enrolled 24 cat‐asthmatic patients with GINA 1 asthma. At baseline,

  Clinical & Experimental Allergy

  Wed Oct 09, 2019 12:59
• Journal of Immunotherapy - Current Issue
• Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma

  The aim of this study was to provide a basis for the theory that the combination of conventional chemotherapy and immunotherapy would be an effective treatment for osteosarcoma. Here, the expression of programmed death ligand 1 (PD-L1) in 26 clinical osteosarcoma tissue samples collected before and after chemotherapy was analyzed. The effects of osteosarcoma cells treated with doxorubicin, a conventional chemotherapeutic agent, on the proliferati

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell–specific Stimulation and Therapeutic Monoclonal Antibodies

  Tumor antigen–targeting monoclonal antibodies (mAbs) are an important element of current cancer therapies. Some of these therapeutic mAbs enable antibody-dependent cell mediated cytotoxicity (ADCC) against tumor cells. However, cancer-related functional impairment of immune effector cells may limit the clinical efficacy of antibody treatments. We reckoned that combining mAbs with cell-based immunotherapies would provide a clinically relevant syne

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature

  The clinical validity and utility of complex biomarkers have not been extensively studied in bladder cancer. Three patients with nonmuscle invasive bladder cancer [1 patient with an exceptional response; complete response (CR) for 30 months] who failed intravesical BCG were evaluated using an NYS CLEP approved assay, Immune Report Card, which measures programmed death-ligand 1 expression, CD8+ T-cell infiltration pattern, mutational burden, and g

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• Linear IgA Disease of the Gingiva Following Nivolumab Therapy

  Immunotherapy has advanced the treatment of solid organ malignancies. Although generally well tolerated, treatment with immune checkpoint inhibitors can be complicated by immune-related adverse events, some of which are relatively uncommon. We report the first case of gingival linear immunoglobulin A disease related to treatment with an antiprogrammed cell death protein 1 antibody. A 73-year-old male with advanced non–small cell lung cancer achie

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis

  Immunotherapy with checkpoint inhibitors (ICI) is widely used to treat a variety of neoplasms. ICI can induce an immune response against cancer; however, ICI can also induce autoimmunity, an undesirable side effect. Autoimmune colitis is one of the most well-known and troubling side effects of ICI. In this report, we described a series of 5 patients who developed ICI-induced colitis. During the course of this complication, all developed Clostridi

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report

  Immunotherapies such as the cytotoxic T-lymphocyte–associated protein 4 inhibitor ipilimumab and the programmed cell death protein 1 inhibitor nivolumab have become ubiquitous in cancer treatment. Recently, the FDA approved nivolumab with or without ipilimumab for the treatment of refractory small cell lung cancer. Immunotherapies increase the immune response to cancer cells by interfering with inhibitory molecular pathways that prevent tumor cel

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication

  Pembrolizumab is a humanized antibody that targets the programmed death-1 receptor expressed in T cells with high selectivity. This therapeutic is of great importance in cancer immunotherapy yet managing the potential immune-related adverse events remains a concern. Here, we report a rare case of mucous membrane pemphigoid in the oral mucosa, upper respiratory tract, and conjunctiva of a patient with ovarian adenocarcinoma without cutaneous manif

  Journal of Immunotherapy - Current Issue

  Thu Oct 10, 2019 13:39
• ScienceDirect Publication: Annals of Allergy, Asthma & Immunology
• Cardiopulmonary Exercise Testing for Pediatric Exercise Induced Dyspnea Especially in Patients who Failed Asthma Treatment

  Publication date: Available online 9 October 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Rajeev Bhatia

  ScienceDirect Publication: Annals of Allergy, Asthma & Immunology

  Thu Oct 10, 2019 03:09
• Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease

  Publication date: Available online 9 October 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Ryan C. Eid, Eden Wudneh, Soombal Zahid, Katherine Cahill, Elina Jerschow

  ScienceDirect Publication: Annals of Allergy, Asthma & Immunology

  Thu Oct 10, 2019 03:09
• Clinical response to omalizumab in patients with hereditary alpha tryptasemia

  Publication date: Available online 9 October 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Lybil B. Mendoza Alvarez, Russell Barker, Celeste Nelson, Tom DiMaggio, Kelly D. Stone, Joshua D. Milner, Jamie A. Rosenthal, Daniel H. Petroni, Sara C. Glover, Jonathan J. Lyons

  ScienceDirect Publication: Annals of Allergy, Asthma & Immunology

  Thu Oct 10, 2019 03:09